Global Hemp-derived Cannabidiol Market Size study, by Source Type (Hemp, Marijuana), by Sales Type (B2B, B2C), by End-use (Medical, Personal Use), and Regional Forecasts 2022-2032

The Global Hemp-derived Cannabidiol Market is valued at approximately USD 7.91 billion in 2023 and is anticipated to expand at a vigorous CAGR of more than 15.60% over the forecast period 2024–2032. As the global wellness industry converges with cannabis innovation, cannabidiol (CBD) derived from hemp has emerged as a transformative force in both medical and consumer markets. With its non-psychoactive profile and broad therapeutic potential, hemp-derived CBD is rapidly permeating sectors ranging from chronic pain management and anxiety relief to skincare, sports recovery, and neurological treatment. The market has become a launchpad for pharma-validated cannabinoid therapeutics as well as lifestyle-focused formulations, reshaping how society conceptualizes plant-based medicine.

This surging adoption is driven by evolving consumer preferences toward natural alternatives, widespread legislative reforms that decriminalize cannabis extracts, and increasing clinical evidence supporting the efficacy of CBD in managing a range of disorders. Market players are doubling down on research to discover more targeted delivery mechanisms—such as nano-emulsified capsules and transdermal patches—while also streamlining supply chains to guarantee purity and traceability. However, regulatory inconsistencies across jurisdictions, especially in labeling and permissible THC content, continue to present significant hurdles to global scalability. In addition, product saturation and misinformation in unregulated online markets hinder consumer confidence and make brand differentiation a complex endeavor.

Major stakeholders are pivoting to compliance-first strategies, investing in Good Manufacturing Practices (GMP) certifications and securing U.S. FDA or EMA approvals for prescription-grade CBD therapies. Simultaneously, blockchain integration in supply tracking and AI-driven consumer personalization platforms are shaping the future of CBD e-commerce. The sector is also witnessing a strategic convergence of pharma giants, biotech startups, and traditional consumer goods brands vying to capture cross-category market share—often through licensing agreements, M&A activities, or co-branded formulations that combine hemp extract with functional ingredients like adaptogens or probiotics.

The global CBD market is increasingly bifurcated between medical-grade applications and over-the-counter (OTC) wellness products. In the medical realm, hemp-derived cannabidiol is gaining ground in treating epilepsy, inflammation, and neurodegenerative conditions, with insurance coverage gradually expanding in developed nations. On the consumer side, the market is marked by robust demand for tinctures, gummies, skincare, beverages, and pet supplements. Brands are customizing their offerings based on demographic nuances, with personalized dosing protocols and bioavailability metrics playing a central role in retaining long-term users and improving treatment adherence.

Regionally, North America continues to dominate the hemp-derived CBD market, driven by progressive regulatory landscapes in the U.S. and Canada, and a thriving ecosystem of vertically integrated producers. Europe is quickly catching up, particularly in countries like Germany, Switzerland, and the UK where medical cannabis frameworks are rapidly maturing. Asia Pacific is emerging as the next growth frontier, fueled by policy liberalization and a resurgence of traditional plant-based therapies. Meanwhile, Latin America and the Middle East & Africa are witnessing early-stage development supported by international partnerships, favorable climates for hemp cultivation, and rising consumer awareness.

Major market player included in this report are:
• Aurora Cannabis Inc.
• Elixinol Wellness Limited
• Medical Marijuana, Inc.
• Charlotte's Web Holdings, Inc.
• Canopy Growth Corporation
• CV Sciences, Inc.
• Endoca BV
• Isodiol International Inc.
• HempMeds
• Green Roads
• Tilray Brands, Inc.
• Medterra CBD
• CBD American Shaman
• GW Pharmaceuticals PLC
• Joy Organics

The detailed segments and sub-segment of the market are explained below:

By Source Type
• Hemp
• Marijuana

By Sales Type
• B2B
• B2C

By End-use
• Medical
• Personal Use

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical Year – 2022
• Base Year – 2023
• Forecast Period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.